日本のジェネリック医薬品市場動向

Abstract

The Japanese pharmaceutical market is the second largest in the world. The government has recently introduced new ' stable supply' rules, to be implemented by 2011, in order to create a more high profile, better-regarded local generic industry. One major change in 2006 has been the issuing of new prescription forms which allow a doctor to authorise the dispensing of a generic drug. This report provides detailed information on the generic drugs market.

According to the JGPMA, generics account for around 16% of the market by volume, and around 6.0% by value. This is a similar percentage to that in France or Spain. Generics are not new in Japan, but they have a low profile and a poor reputation. Many people see them as inferior to branded products. Many old brands in Japan are still widely prescribed, despite patent expiry. The government has recently introduced new ' stable supply' rules, to be implemented by 2011, in order to create a more high profile, better-regarded local generic industry.

The pricing system is not helpful for generics. All prescription drug prices are kept low by the government, with arbitrary price cuts on a regular basis. Patients and prescribers therefore have little incentive to use generics. Pharmacists and hospitals on the other hand, obtain revenues from drug sales, and are keen to dispense higher priced products. Some reforms of the pricing and reimbursement system have been made, although their effect so far appears to have been limited. One major change in 2006 has been the issuing of new prescription forms which allow a doctor to authorise the dispensing of a generic drug. There is also now a small cash incentive for doctors and pharmacists to prescribe/dispense generics.

Japan has a sizeable but very fragmented generic industry. A few players, such as Sawai and Towa, are attempting to boost the image of the sector, but most companies are undercapitalised and unable to make the necessary investments. Only a handful of overseas generic manufacturers have direct operations in Japan.

This in-depth report provides a wide-ranging examination of the generic pharmaceuticals market, including the operating environment, current market size, future prospects and five-year market projections.

Table of Contents

EXECUTIVE SUMMARY

MARKET OVERVIEW

• Key Facts

BACKGROUND

• Geographic
• Political
• Economic

DEMOGRAPHIC DATA

• Population
  • Population of Major Cities, 1995 & 2000 (000s)
  • Population by Prefecture, 2000 (000s)
• Principal Demographic Indicators
  • Principal Demographic Indicators 1996-2003
• Causes of Death
• Morbidity
  • Patients Being Treated for Chronic Illness, 1999
• Infectious diseases
  • HIV/AIDS
  • Reported Infectious Diseases, 1996-2000
    • Tobacco consumption

HEALTHCARE SYSTEM

• Organisation
  • Health Insurance
• Expenditure
  • Total Reported Health Spending*, 1990-2001
• Healthcare Infrastructure
  • Hospitals
  • Hospitals by Type, 1996-2003
  • Total Hospital Beds, 1996-2003
  • Ambulatory care
  • Number of Clinics, 1995-2001
  • Number of Clinics by Sector, 2001
• Medical Personnel
  • Medical Personnel, 1996-2000

GENERIC PHARMACEUTICAL MARKET

• In Context
• Current size
  • Positive signs?
• Projections/Outlook
  • Projected Generic Market, 2005-2010
  • SWOT Analysis Of the Japanese Generic Market
• Regulatory
  • Pharmaceutical Bureau
  • Drug Lag
• Pricing & Reimbursement
  • Yakkasa
  • Price reductions
  • Generic drug pricing & reimbursement
• Intellectual Property
  • Data exclusivity
  • Exclusion of Use
  • Patent term extensions
• Domestic Production
  • JGPMA
  • JGPMA Members, 2005
  • Japan Generic Pharmaceutical Research Group
  • Merck Hoei
  • Morishita Jintan
  • Nippon Hexal
  • Sawai Pharmaceutical Co Ltd
  • Towa Pharmaceutical
  • Towa, Sales by Therapeutic Area, 2004

DIRECTORY

• Regulators
• Trade Bodies
• Manufacturers